MeiraGTx (MGTX) investor relations material

Executive summary

• Report covers the quarter ended March 31, 2026, for a clinical-stage genetic medicines company with four late-stage clinical programs and a broad pipeline, supported by in-house manufacturing and proprietary gene regulation technology.

• Achieved FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year Phase 1 data for radiation-induced xerostomia.

• Strategic transactions included reacquisition of bota-vec (RPGR Product) from Janssen/J&J, a collaboration with Eli Lilly for ophthalmology gene therapies and riboswitch technology, and a major partnership with Hologen for AI-driven CNS therapies.

• Completed a $100 million public equity offering in April 2026 to strengthen liquidity and extend cash runway into the second half of 2028.

• Strengthened leadership with new Chief Development Officer and Chief Scientific Officer for Ophthalmology.

Financial highlights

• Net loss for Q1 2026 was $46.3 million ($0.57 per share), compared to $40.0 million ($0.51 per share) in Q1 2025, driven by R&D and G&A expenses.

• Total/service revenue was $0.3 million, down from $1.9 million year-over-year, due to winding down of service revenue from the Janssen agreement.

• Operating expenses decreased to $41.1 million from $43.5 million year-over-year, with R&D at $32.0 million and G&A at $8.9 million.

• Cash, cash equivalents, and restricted cash totaled $73.8 million as of March 31, 2026, up from $68.2 million at year-end 2025.

• Cash provided by operations was $17.8 million, primarily due to $55 million in advance payments from Hologen.

Outlook and guidance

• Current cash, tax incentive receivable, $100 million equity raise, and $95 million due from Hologen expected to fund operations into the second half of 2028.

• Plans to file for approval and launch two wholly-owned therapies (AAV2-hAQP1 and bota-vec) within two years.

• Pivotal Phase 2 AQUAx2 data for AAV2-hAQP1 expected in Q2 2027, supporting potential BLA filing and U.S. launch in early 2028.

• Phase 3 study initiation for AAV-GAD in Parkinson's disease anticipated in coming months.

• Additional capital may be required for future development and commercialization activities.